Vitekta
Drug
Gilead Sciences Inc
Total Payments
$180,979
Transactions
26
Doctors
1
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $21,000 | 1 | 0 |
| 2019 | $29,215 | 2 | 0 |
| 2018 | $65,703 | 6 | 0 |
| 2017 | $65,061 | 17 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $180,979 | 26 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Weight gain and Metabolic Parameters among Persons with HIV Receiving Integrase Strand Transfer Inhibitors in the United States and Canada | Gilead Sciences, Inc. | $104,215 | 0 |
| A Phase 2/3 multicenter, open-label, Multicohort, 2-part Study Evaluating Pharmacokinetics, Safety, and Antiviral Activitiy of Elvitegravir Administered with a Background Regimen Containing a Ritonavir-boosted Protease Inhibitor in HIV-1 Infected, Antiretroviral Treatment-Experienced Pediatric Subjects | Gilead Sciences Inc | $50,826 | 0 |
| A Phase 2, Open-Label, Multicenter Study of the Safety of Ritonavir-Boosted GS 9137 (GS 9137/r) Administered in Combination with Other Antiretroviral Agents for the Treatment of HIV 1 Infected Subjects | Gilead Sciences Inc | $12,382 | 0 |
| A Phase 2/3 multicenter, open-label, Multicohort, 2-part Study Evaluating Pharmacokinetics, Safety, and Antiviral Activitiy of Elvitegravir Administered with a Background Regimen Containing a Ritonavir-boosted Protease Inhibitor in HIV-1 Infected, Antiretroviral Treatment-Experienced Pediatric Subjects | Gilead Sciences, Inc. | $9,935 | 0 |
| A Multicenter, Randomized, Double-Blind, Phase 3 Study of the Safety and Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r, GS-9137/r) Versus Raltegravir (RGV) Each Administered With a Background Regimen in HIV-1 Infected, Antiretroviral Treatment-Experienced Adults | Gilead Sciences Inc | $1,853 | 1 |
| A Phase 2, Randomized Study of the Treatment of Antiretroviral Treatment-Experienced, HIV-1 Infected Subjects Comparing Ritonavir -Boosted GS-9137 (GS-9137/r) Versus a Comparator Ritonavir-Boosted Protease Inhibitor (CPI/r) in Combination with a Background Antiretroviral Therapy | Gilead Sciences, Inc. | $1,200 | 0 |
| A Multicenter, Randomized, Double-Blind, Phase 3 Study of the Safety and Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r, GS-9137/r) Versus Raltegravir (RGV) Each Administered With a Background Regimen in HIV-1 Infected, Antiretroviral Treatment-Experienced Adults | Gilead Sciences, Inc. | $568.00 | 0 |
Top Doctors Receiving Payments for Vitekta
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Los Angeles, CA | $179,125 | 25 |
| , DMD | General Practice | Calabasas, CA | $1,853 | 1 |
Ad
Manufacturing Companies
- Gilead Sciences, Inc. $115,918
- Gilead Sciences Inc $65,061
Product Information
- Type Drug
- Total Payments $180,979
- Total Doctors 1
- Transactions 26
About Vitekta
Vitekta is a drug associated with $180,979 in payments to 1 healthcare providers, recorded across 26 transactions in the CMS Open Payments database. The primary manufacturer is Gilead Sciences Inc.
Payment data is available from 2017 to 2020. In 2020, $21,000 was paid across 1 transactions to 0 doctors.
The most common payment nature for Vitekta is "Unspecified" ($180,979, 100.0% of total).
Vitekta is associated with 7 research studies, including "Weight gain and Metabolic Parameters among Persons with HIV Receiving Integrase Strand Transfer Inhibitors in the United States and Canada" ($104,215).